Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

How I treat resistant cytomegalovirus infection in hematopoietic cell transplantation recipients.

El Chaer F, Shah DP, Chemaly RF.

Blood. 2016 Dec 8;128(23):2624-2636. Epub 2016 Oct 19. Review.

2.

Analysis of ganciclovir-resistant human herpesvirus 6B clinical isolates using quenching probe PCR methodology.

Hiramatsu H, Suzuki R, Yamada S, Ihira M, Isegawa Y, Kawamura Y, Matsuoka E, Miura H, Yoshikawa T.

Antimicrob Agents Chemother. 2015 May;59(5):2618-24. doi: 10.1128/AAC.04692-14. Epub 2015 Feb 17.

3.

Differential properties of cytomegalovirus pUL97 kinase isoforms affect viral replication and maribavir susceptibility.

Webel R, Hakki M, Prichard MN, Rawlinson WD, Marschall M, Chou S.

J Virol. 2014 May;88(9):4776-85. doi: 10.1128/JVI.00192-14. Epub 2014 Feb 12.

4.

Rapid detection of human cytomegalovirus UL97 and UL54 mutations directly from patient samples.

Hall Sedlak R, Castor J, Butler-Wu SM, Chan E, Cook L, Limaye AP, Jerome KR.

J Clin Microbiol. 2013 Jul;51(7):2354-9. doi: 10.1128/JCM.00611-13. Epub 2013 May 15.

5.

Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo.

Chou S, Hakki M, Villano S.

Antiviral Res. 2012 Aug;95(2):88-92. doi: 10.1016/j.antiviral.2012.05.013. Epub 2012 Jun 1.

6.

Does Cytomegalovirus Develop Resistance following Antiviral Prophylaxis and Treatment in Renal Transplant Patients in Kuwait?

Madi N, Al-Nakib W, Pacsa A.

Adv Virol. 2011;2011:260561. doi: 10.1155/2011/260561. Epub 2011 Mar 24.

7.

Cytomegalovirus retinitis and the acquired immunodeficiency syndrome--bench to bedside: LXVII Edward Jackson Memorial Lecture.

Jabs DA.

Am J Ophthalmol. 2011 Feb;151(2):198-216.e1. doi: 10.1016/j.ajo.2010.10.018. Epub 2010 Dec 18.

8.

Antiviral drug resistance of human cytomegalovirus.

Lurain NS, Chou S.

Clin Microbiol Rev. 2010 Oct;23(4):689-712. doi: 10.1128/CMR.00009-10. Review.

9.

Stereoselective phosphorylation of cyclopropavir by pUL97 and competitive inhibition by maribavir.

Gentry BG, Kamil JP, Coen DM, Zemlicka J, Drach JC.

Antimicrob Agents Chemother. 2010 Aug;54(8):3093-8. doi: 10.1128/AAC.00468-10. Epub 2010 Jun 14.

10.

Recombinant phenotyping of cytomegalovirus UL97 kinase sequence variants for ganciclovir resistance.

Chou S.

Antimicrob Agents Chemother. 2010 Jun;54(6):2371-8. doi: 10.1128/AAC.00186-10. Epub 2010 Apr 12.

11.

Successful valganciclovir treatment of post-transplant cytomegalovirus infection in the presence of UL97 mutation N597D.

Iwasenko JM, Scott GM, Rawlinson WD, Keogh A, Mitchell D, Chou S.

J Med Virol. 2009 Mar;81(3):507-10. doi: 10.1002/jmv.21397.

12.

Rapid detection directly from patient serum samples of human cytomegalovirus UL97 mutations conferring ganciclovir resistance.

Castor J, Cook L, Corey L, Jerome KR.

J Clin Microbiol. 2007 Aug;45(8):2681-3. Epub 2007 May 30.

13.

Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates.

Scott GM, Weinberg A, Rawlinson WD, Chou S.

Antimicrob Agents Chemother. 2007 Jan;51(1):89-94. Epub 2006 Oct 16.

14.

Phenotyping of cytomegalovirus drug resistance mutations by using recombinant viruses incorporating a reporter gene.

Chou S, Van Wechel LC, Lichy HM, Marousek GI.

Antimicrob Agents Chemother. 2005 Jul;49(7):2710-5.

15.

Human cytomegalovirus resistance to antiviral drugs.

Gilbert C, Boivin G.

Antimicrob Agents Chemother. 2005 Mar;49(3):873-83. Review. No abstract available.

16.
17.

Molecular methods for cytomegalovirus surveillance in bone marrow transplant recipients.

Weinberg A, Schissel D, Giller R.

J Clin Microbiol. 2002 Nov;40(11):4203-6.

18.

Supplemental Content

Support Center